146 related articles for article (PubMed ID: 32741961)
1. Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT).
Beksac M; Kröger N; Byrne JL; Ganser A; Yeğin ZA; Schönland S
Bone Marrow Transplant; 2021 Mar; 56(3):529-531. PubMed ID: 32741961
[No Abstract] [Full Text] [Related]
2. Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party.
Hayden PJ; Eikema DJ; de Wreede LC; Koster L; Kröger N; Einsele H; Minnema M; Dominietto A; Potter M; Passweg J; Bermúdez A; Nguyen-Quoc S; Platzbecker U; Tischer J; Ciceri F; Veelken JH; Ljungman P; Schaap N; Forcade E; Carella AM; Gandemer V; Arcese W; Bloor A; Olivieri A; Vincent L; Beksac M; Schönland S; Yakoub-Agha I
Bone Marrow Transplant; 2021 Oct; 56(10):2367-2381. PubMed ID: 33976382
[TBL] [Abstract][Full Text] [Related]
3. Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP.
Hayden PJ; Iacobelli S; Pérez-Simón JA; van Biezen A; Minnema M; Niittyvuopio R; Schönland S; Meijer E; Blaise D; Milpied N; Márquez-Malaver FJ; Veelken JH; Maertens J; Michallet M; Cammenga J; N'Guyen S; Niederwieser D; Hunault-Berger M; Bourhis JH; Passweg J; Bermudez A; Chalandon Y; Yakoub-Agha I; Garderet L; Kröger N
Eur J Haematol; 2020 Mar; 104(3):181-189. PubMed ID: 31737951
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Domingo-Domènech E; Boumendil A; Climent F; Socié G; Kroschinsky F; Finel H; Vandenbergue E; Nemet D; Stelljes M; Bittenbring JT; Robinson S; Montoto S; Sureda A; Dreger P;
Bone Marrow Transplant; 2020 Mar; 55(3):633-640. PubMed ID: 31695173
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT.
Vincent L; Gras L; Ceballos P; Finke J; Passweg J; Harel S; Rosinol L; Minnema M; Teipel R; van Doesum J; Hänel M; Lenain P; Botella-Garcia C; Koenecke C; Ducastelle S; Sanz J; Schroyens W; Zuckerman T; Monaco F; Koster L; de Wreede L; Hayden PJ; Schönland S; Yakoub-Agha I; Beksac M
Bone Marrow Transplant; 2022 Mar; 57(3):499-501. PubMed ID: 35013536
[No Abstract] [Full Text] [Related]
6. Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma.
Fasslrinner F; Stölzel F; Kramer M; Teipel R; Brogsitter C; Morgner A; Arndt C; Bachmann M; Hänel M; Röllig C; Kotzerke J; Schetelig J; Bornhäuser M
Biol Blood Marrow Transplant; 2020 Apr; 26(4):691-697. PubMed ID: 31730919
[TBL] [Abstract][Full Text] [Related]
7. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D
Biol Blood Marrow Transplant; 2014 Jan; 20(1):66-72. PubMed ID: 24141006
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
Maymani H; Lin P; Saliba RM; Popat U; Bashir Q; Shah N; Patel K; Parmar S; Kebriaei P; Hosing C; Ciurea S; Andersson B; Shpall E; Champlin R; Srour SA; Qazilbash MH
Biol Blood Marrow Transplant; 2019 May; 25(5):1039-1044. PubMed ID: 30639822
[TBL] [Abstract][Full Text] [Related]
9. Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party.
Sobh M; Michallet M; Dubois V; Iacobelli S; Koster L; Van Biezen A; Fegueux N; Tabrizi R; Finke J; El-Cheikh J; Schipperus M; Meijer E; von dem Borne P; Petersen E; Russell N; Tholouli E; Passweg J; Garban F; Maertens J; Chevalier P; Maillard N; Volin L; Francois S; Lioure B; Beguin Y; Gluckman E; Ruggeri A; Garderet L; Kröger N
Haematologica; 2017 Jul; 102(7):e271-e274. PubMed ID: 28428268
[No Abstract] [Full Text] [Related]
10. Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT.
Sureda A; Genadieva Stavrik S; Boumendil A; Finel H; Khvedelidze I; Dietricht S; Dreger P; Hermine O; Kyriakou C; Robinson S; Schmitz N; Schouten HC; Tanase A; Montoto S
Bone Marrow Transplant; 2020 Nov; 55(11):2170-2179. PubMed ID: 32415225
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report.
Sahebi F; Garderet L; Kanate AS; Eikema DJ; Knelange NS; Alvelo OFD; Koc Y; Blaise D; Bashir Q; Moraleda JM; Dreger P; Sanchez JF; Ciurea S; Schouten H; Shah NN; Verbeek M; Rösler W; Diez-Martin JL; Schoenland S; D'Souza A; Kröger N; Hari P
Biol Blood Marrow Transplant; 2019 Feb; 25(2):335-342. PubMed ID: 30243581
[TBL] [Abstract][Full Text] [Related]
13. Treosulfan conditioning for allogeneic transplantation in multiple myeloma - improved overall survival in first line haematopoietic stem cell transplantation - a large retrospective study by the Chronic Malignancies Working Party of the EBMT.
Gran C; Wang J; Nahi H; Koster L; Gahrton G; Einsele H; Niittyvoupio R; Edinger M; Beelen D; Ciceri F; Bornhäuser M; Finke J; de Wreede LC; Ljungman P; Mielke S; Tischer J; Garderet L; Schönland S; Yakoub-Agha I; Kröger N
Br J Haematol; 2020 Jun; 189(5):e213-e217. PubMed ID: 32301111
[No Abstract] [Full Text] [Related]
14. European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party.
McLornan DP; Sirait T; Hernández-Boluda JC; Czerw T; Hayden P; Yakoub-Agha I
Curr Res Transl Med; 2021 Jan; 69(1):103267. PubMed ID: 33069640
[TBL] [Abstract][Full Text] [Related]
15. Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Passweg JR; Labopin M; Christopeit M; Cornelissen J; Pabst T; Socié G; Russel N; Yakoub-Agha I; Blaise D; Gedde-Dahl T; Labussière-Wallet H; Malladi R; Forcade E; Maury S; Polge E; Lanza F; Gorin NC; Mohty M; Nagler A
Biol Blood Marrow Transplant; 2020 Apr; 26(4):659-664. PubMed ID: 31759159
[TBL] [Abstract][Full Text] [Related]
16. Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.
Schneidawind C; Duerr-Stoerzer S; Faul C; Kanz L; Weisel K; Bethge W; Schneidawind D
Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28470884
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
Morris C; Iacobelli S; Gahrton G; van Biezen A; Drake M; Garderet L; Potter M; Schattenberg AV; Cornelissen JJ; Hamladji RM; Martelli M; Petersen E; Rovira M; Bandini G; Kroger N; de Witte T
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1054-8. PubMed ID: 25708221
[TBL] [Abstract][Full Text] [Related]
18. The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT.
Tournilhac O; van Gelder M; Eikema DJ; Zinger N; Dreger P; Bornhäuser M; Vucinic V; Scheid C; Cornelissen JJ; Schroeder T; Jindra P; Sengeloev H; Nguyen Quoc S; Stelljes M; Blau IW; Mayer J; Paneesha S; Chevallier P; Forcade E; Kröger N; Blaise D; Gribben J; Nielsen B; Johansson JE; Kyriakou C; Beguin Y; Pioltelli P; Sampol A; McLornan DP; Schetelig J; Hayden PJ; Yakoub-Agha I
Bone Marrow Transplant; 2023 Jun; 58(6):621-624. PubMed ID: 36977926
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Onida F; de Wreede LC; van Biezen A; Eikema DJ; Byrne JL; Iori AP; Schots R; Jungova A; Schetelig J; Finke J; Veelken H; Johansson JE; Craddock C; Stelljes M; Theobald M; Holler E; Schanz U; Schaap N; Bittenbring J; Olavarria E; Chalandon Y; Kröger N
Br J Haematol; 2017 Jun; 177(5):759-765. PubMed ID: 28369779
[TBL] [Abstract][Full Text] [Related]
20. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
